Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10290560" target="_blank" >RIV/00216208:11110/14:10290560 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/14:E0103889

Výsledek na webu

<a href="http://dx.doi.org/10.3109/21681805.2013.814707" target="_blank" >http://dx.doi.org/10.3109/21681805.2013.814707</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/21681805.2013.814707" target="_blank" >10.3109/21681805.2013.814707</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients

Popis výsledku v původním jazyce

Objective. The aim of this study was to evaluate the persistence of first line anticholinergic medication use by patients with overactive bladder (OAB). Data from a hospital outpatient database were matched with information obtained by a telephone surveyof patients to determine which patients discontinued use of anticholinergic medication and to identify the reasons underlying discontinuation. Material and methods. The study group included 377 OAB patients (52 men, 325 women) with a mean age of 60.29 +/- 13.84 years. In total, 189 patients (50.1%) were treated with trospium (median dose 27.86 +/- 12.73 mg), 41 patients (10.9%) with propiverine (28.17 +/- 4.97 mg), nine patients (2.4%) with extended-release tolterodine (4.0 +/- 0 mg), 48 patients (12.7%) with solifenacin (5.94 +/- 1.97 mg) and 90 patients (23.9%) with fesoterodine (6.09 +/- 2.01 mg). Results. The median time for persistence with the first line anticholinergic treatment was 6.53 +/- 3.84 months. Persistence was signific

Název v anglickém jazyce

Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients

Popis výsledku anglicky

Objective. The aim of this study was to evaluate the persistence of first line anticholinergic medication use by patients with overactive bladder (OAB). Data from a hospital outpatient database were matched with information obtained by a telephone surveyof patients to determine which patients discontinued use of anticholinergic medication and to identify the reasons underlying discontinuation. Material and methods. The study group included 377 OAB patients (52 men, 325 women) with a mean age of 60.29 +/- 13.84 years. In total, 189 patients (50.1%) were treated with trospium (median dose 27.86 +/- 12.73 mg), 41 patients (10.9%) with propiverine (28.17 +/- 4.97 mg), nine patients (2.4%) with extended-release tolterodine (4.0 +/- 0 mg), 48 patients (12.7%) with solifenacin (5.94 +/- 1.97 mg) and 90 patients (23.9%) with fesoterodine (6.09 +/- 2.01 mg). Results. The median time for persistence with the first line anticholinergic treatment was 6.53 +/- 3.84 months. Persistence was signific

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scandinavian Journal of Urology

ISSN

2168-1805

e-ISSN

—

Svazek periodika

48

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

79-83

Kód UT WoS článku

000332420100011

EID výsledku v databázi Scopus

—